Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Feasibility test of the SYLVER system to image unruptured intracranial aneurysms using 3D ultrasound compared with 3D rotational angiography

Official title: Proof of Concept Study to Evaluate the Feasibility of a Multimodal Approach Combining Angiography and 3D Ultrasound for the Hemodynamic Analysis of Unruptured, Untreated Intracranial Aneurysms

Run by Resolve Stroke · NCT07864389 · Data updated 2026-11-12

This feasibility study tests whether the SYLVER system can visualize unruptured brain aneurysms as well as the standard 3D rotational angiography technique.

More Unruptured Intracranial Aneurysm trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment15 (estimated)
SponsorResolve Stroke
Industry-sponsored
Locations1 site (Nantes)
StatusRecruiting
StartedOctober 5, 2026
Main results expectedNovember 2026
Study endsDecember 2026
Registry record updatedOctober 13, 2026
Trial IDNCT07864389 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with one or more unruptured, untreated intracranial aneurysms of at least 3 mm, suitable for diagnostic cerebral angiography.

Probably not a fit

Patients without aneurysms or whose anatomy is not compatible with the SYLVER imaging modality may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the SYLVER system, using 3D contrast-enhanced ultrasound to image unruptured intracranial aneurysms. It compares visualization achieved with SYLVER to the reference standard of 3D rotational angiography. Eligible participants are adults with one or more unruptured, untreated aneurysms identified incidentally and requiring diagnostic cerebral angiography within six months. The trial is conducted as an interventional feasibility assessment at Nantes University Hospital with Resolve Stroke as lead sponsor. Enrollment and procedures follow indicated consent and standard safety oversight.

Why it matters

Potential benefit: If successful, patients could benefit from a non-invasive imaging option that complements or precedes traditional angiography.

How similar studies have gone: Prior experiences with ultrasound-based, image-guided visualization of intracranial vessels have shown promise, but this exact multimodal feasibility approach is exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients (≥ 18 years of age)
* Informed consent signed by the patient
* Enrolled in a social security program or covered by an equivalent program
* Presence of one or more unruptured, untreated intracranial aneurysms; typically bifurcation aneurysms, incidentally discovered, with a size of ≥ 3 mm; located at the base of the polygon of Willis in the Sylvian bifurcation, the anterior or posterior communicating artery, or the carotid or basilar terminal segments
* Indications for diagnostic cerebral arteriography within a 6-month period following the discovery of one or more unruptured aneurysms

Exclusion Criteria:

* Unusable temporal window
* Withdrawal of Consent by the Patient
* Cancellation of the appointment for a cerebral angiography
* At the investigator's initiative, in the patient's best interest

Where it's running

  • Nantes University Hospital
    Nantes, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.